This is a reply to the comment by Ivan Berlin and Daniel Thomas on our recently published work [1]. The authors of “A Systematic Review and Meta-Analysis of Hospitalised Current Smokers and COVID-19” greatly appreciate Ivan Berlin and Daniel Thomas’ comments. However, we believe that the comment, as a whole, presents a biased interpretation of the information.

Berlin and Thomas start their comment stating that results “confirmed the protective effect of current smoking on the likelihood of hospitalization”. However, in our opinion, they make an incorrect interpretation of the phrase (it is taken out of context), since such sentence was used in the L’Abbé graphic. The so-called [2] graphs are a good way to visualize data based on event rates. In these graphs the event rate in the intervention group of a study is plotted against the event rate in the control group. Then, if a type of intervention to have a protective effect (i.e., to make an adverse outcome such as less likely hospitalization) is expected, the studies should mainly be located in the lower right corner of the L’Abbé graph. This is the case in our paper: the “protective effect” is the fact of being a current smoker over the fact of hospitalization. It is not stated in any case that the protective effect is tobacco, but rather that there is a lower prevalence of smoking among patients hospitalized for COVID-19 than expected.

It is likely that this association does not involve a causal relationship and, of course, as it is clearly indicated in the paper, smoking is not recommended as prevention or treatment of COVID-19. The association could be due to many factors that could include common smoking habits, increased likelihood of cross-immunity when smokers are infected by other coronavirus [3], anti-inflammatory effect of nicotine [4–6], increased hygienic habits, giving up smoking when became sick being considered non-smokers, the definition of “current smoker” is not always provided, etc. A detailed argumentation of all these potential issues is included in the discussion section of the paper. Coming back to the main focus of the results, what seems clear is the finding of an underrepresentation of smokers among COVID-19 hospitalized patients, which has been confirmed by other meta-analysis [7] and even by the European Commission [8].
Berlin and Thomas also stated that “none of the included papers reported on biochemical verification of smoking status”. We agree with this assessment and consider that it would be very interesting to include it (biochemical verification and COVID-19) in future reviews when these data are available, especially when most recent studies indicate a negative association between smoking prevalence and occurrence of COVID-19 at the population level in 38 European countries [9].

Furthermore, Ivan Berlin and Daniel Thomas indicated that “It is not surprising that the prevalence rate of smoking is substantially lower among individuals hospitalized for COVID-19 in each country than in their general population and shows a relatively low measure of dispersion”. Contrariwise, we do find it surprising that the prevalence of smoking is substantially lower among people hospitalized by COVID-19, considering that smoking is known to increase the onset of multiple respiratory diseases [10]. In addition, smokers are known to have a significantly higher risk of chronic respiratory disease and acute respiratory infections [11]. Even current smokers have an increased risk of developing influenza compared to non-smokers [12]. Smoking was also significantly associated with MERS-CoV [13].

Finally, Berlin and Thomas stated that “speculation about biological mechanisms is adequate only if a cause to effect relationship between smoking and hospitalization for COVID-19 is demonstrated in prospective studies. A protective effect should be evoked with extreme caution because a biased message may induce smokers to continue to smoke or to relapse to smoking to protect themselves from COVID-19”. We are sorry that the authors have greatly misrepresented our conclusion that in no case was what they described. However, the fact that tobacco is a poison that kills eight million people a year in the world does not mean that an epidemiological finding, which might open new research lines, should be despised. Our analysis is based on consistent epidemiological data and proposes a physiological substrate already demonstrated for inflammatory diseases [6,14]. This is the advantage of working in a multidisciplinary team like ours formed by doctors, epidemiologists and physiologists. We believe that the pandemic has been the domain of epidemiologists, virologists, behavioral psychologists and respiratory researchers, and the neuro sides to it are just coming through [15].

In our opinion, Berlin and Thomas have obviated these multidisciplinary approaches in their comment, and have distorted the message of our study, placing the focus on an erroneous interpretation, suggesting that our findings might induce smokers to keep or go back to smoking to protect themselves from COVID-19. In our work, the surprising finding is just the opposite: that the cases of COVID-19 do not group together with smokers. The clue must be investigated.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Gonzalez-Rubio, J.; Navarro-Lopez, C.; Lopez-Najera, E.; Lopez-Najera, A.; Jimenez-Diaz, L.; Navarro-Lopez, J.D.; Najera, A. A Systematic Review and Meta-Analysis of Hospitalised Current Smokers and COVID-19. Int. J. Environ. Res. Public Health 2020, 17, 7394. [CrossRef] [PubMed]
2. L’Abbe, K.A.; Detsky, A.S.; O’Rourke, K. Meta-analysis in clinical research. Ann. Intern. Med. 1987, 107, 224–233. [CrossRef] [PubMed]
3. Reina, J.; Lopez-Causape, C.; Rojo-Molinero, E.; Rubio, R. Clinico-epidemiological characteristics of acute respiratory infections caused by coronavirus OC43, NL63 and 229E. Rev. Clin. Esp. 2014, 214, 499–504. [CrossRef] [PubMed]
4. Gomes, J.P.; Watad, A.; Shoenfeld, Y. Nicotine and autoimmunity: The lotus’ flower in tobacco. Pharmacol. Res. 2018, 128, 101–109. [CrossRef] [PubMed]
5. Gonzalez-Rubio, J.; Navarro-Lopez, C.; Lopez-Najera, E.; Lopez-Najera, A.; Jimenez-Diaz, L.; Navarro-Lopez, J.D.; Najera, A. Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm. Front. Immunol. 2020, 11, 1359. [CrossRef] [PubMed]
6. Yamada, M.; Ichinose, M. The cholinergic anti-inflammatory pathway: An innovative treatment strategy for respiratory diseases and their comorbitides. Curr. Opin. Pharmacol. 2018, 40, 18–25. [CrossRef] [PubMed]
7. Farsalinos, K.; Barbouni, A.; Poulas, K.; Polosa, R.; Caponnetto, P.; Niaura, R. Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: A systematic review and meta-analysis. *Ther. Adv. Chronic. Dis.* 2020, 11, 2040622320935765. [CrossRef] [PubMed]

8. Wenzl, T. Smoking and COVID-19: Did we overlook representativeness? *Tob. Induc. Dis.* 2020, 18, 89. [CrossRef] [PubMed]

9. Tsigaris, P.; da Silva, J.A.T. Smoking Prevalence and COVID-19 in Europe. *Nicotine Tob. Res.* 2020, 22, 1646–1649. [CrossRef] [PubMed]

10. Peiffer, G.; Underner, M.; Perriot, J. The respiratory effects of smoking. *Rev. Pneumol. Clin.* 2018, 74, 133–144. [CrossRef] [PubMed]

11. Almirall, J.; Serra-Prat, M.; Bolibar, I.; Balasso, V. Risk Factors for Community-Acquired Pneumonia in Adults: A Systematic Review of Observational Studies. *Respiration* 2017, 94, 299–311. [CrossRef] [PubMed]

12. Lawrence, H.; Hunter, A.; Murray, R.; Lim, W.S.; McKeever, T. Cigarette smoking and the occurrence of influenza—Systematic review. *J. Infect.* 2019, 79, 401–406. [CrossRef] [PubMed]

13. Alraddadi, B.M.; Watson, J.T.; Almarashi, A.; Abedi, G.R.; Turkistani, A.; Sadran, M.; Housa, A.; Almazrooa, M.A.; Alraihan, N.; Banjar, A.; et al. Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Illness in Humans, Saudi Arabia, 2014. *Emerg. Infect. Dis.* 2016, 22, 49–55. [CrossRef] [PubMed]

14. Sandborn, W.J.; Tremaine, W.J.; Offord, K.P.; Lawson, G.M.; Petersen, B.T.; Batts, K.P.; Croghan, I.T.; Dale, L.C.; Schroeder, D.R.; Hurt, R.D. Transdermal nicotine for mildly to moderately active ulcerative colitis: A randomized, double-blind, placebo-controlled trial. *Ann. Intern. Med.* 1997, 126, 364–371. [CrossRef] [PubMed]

15. Romero-Sanchez, C.M.; Diaz-Maroto, I.; Fernandez-Diaz, E.; Sanchez-Larsen, A.; Layos-Romero, A.; Garcia-Garcia, J.; Gonzalez, E.; Redondo-Penas, I.; Perona-Moratalla, A.B.; Del Valle-Perez, J.A.; et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. *Neurology* 2020, 95, e1060–e1070. [CrossRef] [PubMed]

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).